{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:11:09Z","timestamp":1769598669845,"version":"3.49.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T00:00:00Z","timestamp":1479081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T00:00:00Z","timestamp":1479081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1038\/bmt.2016.250","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T14:46:37Z","timestamp":1479134797000},"page":"228-237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients"],"prefix":"10.1038","volume":"52","author":[{"given":"R","family":"Oostvogels","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Kneppers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M C","family":"Minnema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R C","family":"Doorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L E","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M E","family":"Emmelot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Spierings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Slaper-Cortenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Westinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Goulmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H M","family":"Lokhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Mutis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,14]]},"reference":[{"key":"BFbmt2016250_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K . Multiple myeloma. N Engl J Med 2011; 364: 1046\u20131060.","journal-title":"N Engl J Med"},{"key":"BFbmt2016250_CR2","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/S0140-6736(96)90871-5","volume":"347","author":"LF Verdonck","year":"1996","unstructured":"Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ . Graft-versus-myeloma effect in two cases. Lancet 1996; 347: 800\u2013801.","journal-title":"Lancet"},{"key":"BFbmt2016250_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1083-8791(03)00075-2","volume":"9","author":"CA Huff","year":"2003","unstructured":"Huff CA, Fuchs EJ, Noga SJ, O'Donnell PV, Ambinder RF, Diehl L et al. Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biol Blood Marrow Transplant 2003; 9: 312\u2013319.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016250_CR4","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1056\/NEJMoa065464","volume":"356","author":"B Bruno","year":"2007","unstructured":"Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110\u20131120.","journal-title":"N Engl J Med"},{"key":"BFbmt2016250_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00130404-200401000-00001","volume":"10","author":"E Goulmy","year":"2004","unstructured":"Goulmy E . Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. Cancer J 2004; 10: 1\u20137.","journal-title":"Cancer J"},{"key":"BFbmt2016250_CR6","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1182\/blood-2007-11-125492","volume":"112","author":"L Hambach","year":"2008","unstructured":"Hambach L, Vermeij M, Buser A, Aghai Z, van der Kwast T, Goulmy E . Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors. Blood 2008; 112: 1844\u20131852.","journal-title":"Blood"},{"key":"BFbmt2016250_CR7","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1073\/pnas.0530192100","volume":"100","author":"WA Marijt","year":"2003","unstructured":"Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn MA et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100: 2742\u20132747.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbmt2016250_CR8","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-10-1340","volume":"16","author":"RM Spaapen","year":"2010","unstructured":"Spaapen RM, Groen RW, van den Oudenalder K, Guichelaar T, van Elk M, Aarts-Riemens T et al. Eradication of medullary multiple myeloma by CD4+ cytotoxic human T lymphocytes directed at a single minor histocompatibility antigen. Clin Cancer Res 2010; 16: 5481\u20135488.","journal-title":"Clin Cancer Res"},{"key":"BFbmt2016250_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.beha.2008.06.001","volume":"21","author":"R Spaapen","year":"2008","unstructured":"Spaapen R, Mutis T . Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 543\u2013557.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFbmt2016250_CR10","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.4049\/jimmunol.149.5.1788","volume":"149","author":"M de Bueger","year":"1992","unstructured":"de Bueger M, Bakker A, Van Rood JJ, Van der Woude F, Goulmy E . Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992; 149: 1788\u20131794.","journal-title":"J Immunol"},{"key":"BFbmt2016250_CR11","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","volume":"97","author":"PA McSweeney","year":"2001","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390\u20133400.","journal-title":"Blood"},{"key":"BFbmt2016250_CR12","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1182\/blood-2003-11-3862","volume":"103","author":"HM Lokhorst","year":"2004","unstructured":"Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362\u20134364.","journal-title":"Blood"},{"key":"BFbmt2016250_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2217\/imt.13.31","volume":"5","author":"N El-Jurdi","year":"2013","unstructured":"El-Jurdi N, Reljic T, Kumar A, Pidala J, Bazarbachi A, Djulbegovic B et al. Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy 2013; 5: 457\u2013466.","journal-title":"Immunotherapy"},{"key":"BFbmt2016250_CR14","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1182\/blood-2011-11-393801","volume":"119","author":"HM Lokhorst","year":"2012","unstructured":"Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012; 119: 6219\u20136225.","journal-title":"Blood"},{"key":"BFbmt2016250_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1756-8722-6-2","volume":"6","author":"MA Kharfan-Dabaja","year":"2013","unstructured":"Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B et al. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 2013; 6: 2.","journal-title":"J Hematol Oncol"},{"key":"BFbmt2016250_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.bbmt.2005.11.519","volume":"12","author":"G Xia","year":"2006","unstructured":"Xia G, Truitt RL, Johnson BD . Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant 2006; 12: 397\u2013407.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016250_CR17","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2002-01-0023","volume":"100","author":"MY Mapara","year":"2002","unstructured":"Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M . Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002; 100: 1903\u20131909.","journal-title":"Blood"},{"key":"BFbmt2016250_CR18","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1084\/jem.168.6.2391","volume":"168","author":"M Sykes","year":"1988","unstructured":"Sykes M, Sheard MA, Sachs DH . Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med 1988; 168: 2391\u20132396.","journal-title":"J Exp Med"},{"key":"BFbmt2016250_CR19","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1126\/science.285.5426.412","volume":"285","author":"WD Shlomchik","year":"1999","unstructured":"Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412\u2013415.","journal-title":"Science"},{"key":"BFbmt2016250_CR20","doi-asserted-by":"publisher","first-page":"7393","DOI":"10.4049\/jimmunol.172.12.7393","volume":"172","author":"UA Duffner","year":"2004","unstructured":"Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 2004; 172: 7393\u20137398.","journal-title":"J Immunol"},{"key":"BFbmt2016250_CR21","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1182\/blood-2004-08-3032","volume":"105","author":"BE Anderson","year":"2005","unstructured":"Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ . Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 2005; 105: 2227\u20132234.","journal-title":"Blood"},{"key":"BFbmt2016250_CR22","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood-2003-07-2344","volume":"103","author":"WA Bethge","year":"2004","unstructured":"Bethge WA, Hegenbart U, Stuart MJ, Storer BE, Maris MB, Flowers ME et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004; 103: 790\u2013795.","journal-title":"Blood"},{"key":"BFbmt2016250_CR23","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood.V99.4.1442","volume":"99","author":"S Auffermann-Gretzinger","year":"2002","unstructured":"Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, Leong W, Grumet FC, Blume KG et al. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood 2002; 99: 1442\u20131448.","journal-title":"Blood"},{"key":"BFbmt2016250_CR24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/sj.bmt.1705777","volume":"40","author":"H Levenga","year":"2007","unstructured":"Levenga H, Woestenenk R, Schattenberg AV, Maas F, Jansen JH, Raymakers R et al. Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion. Bone Marrow Transplant 2007; 40: 585\u2013592.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016250_CR25","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood.V93.7.2411","volume":"93","author":"VL Reichardt","year":"1999","unstructured":"Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma\u2014a feasibility study. Blood 1999; 93: 2411\u20132419.","journal-title":"Blood"},{"key":"BFbmt2016250_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S1083-8791(00)70027-9","volume":"6","author":"A Liso","year":"2000","unstructured":"Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 621\u2013627.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016250_CR27","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1046\/j.1365-2141.2000.01958.x","volume":"108","author":"S Titzer","year":"2000","unstructured":"Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000; 108: 805\u2013816.","journal-title":"Br J Haematol"},{"key":"BFbmt2016250_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/CJI.0b013e3181facf48","volume":"34","author":"C Rollig","year":"2011","unstructured":"Rollig C, Schmidt C, Bornhauser M, Ehninger G, Schmitz M, Auffermann-Gretzinger S . Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. J Immunother 2011; 34: 100\u2013106.","journal-title":"J Immunother"},{"key":"BFbmt2016250_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1365-2141.2007.06832.x","volume":"139","author":"A Curti","year":"2007","unstructured":"Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C et al. Phase I\/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br J Haematol 2007; 139: 415\u2013424.","journal-title":"Br J Haematol"},{"key":"BFbmt2016250_CR30","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1365-2141.2010.08286.x","volume":"150","author":"Q Yi","year":"2010","unstructured":"Yi Q, Szmania S, Freeman J, Qian J, Rosen NA, Viswamitra S et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol 2010; 150: 554\u2013564.","journal-title":"Br J Haematol"},{"key":"BFbmt2016250_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1365-2249.2012.04642.x","volume":"170","author":"S Hong","year":"2012","unstructured":"Hong S, Li H, Qian J, Yang J, Lu Y, Yi Q . Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin Exp Immunol 2012; 170: 167\u2013177.","journal-title":"Clin Exp Immunol"},{"key":"BFbmt2016250_CR32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","volume":"34","author":"J Rosenblatt","year":"2011","unstructured":"Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine. J Immunother 2011; 34: 409\u2013418.","journal-title":"J Immunother"},{"key":"BFbmt2016250_CR33","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/leu.2012.277","volume":"27","author":"R Oostvogels","year":"2013","unstructured":"Oostvogels R, Minnema MC, van Elk M, Spaapen RM, te Raa GD, Giovannone B et al. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1. Leukemia 2013; 27: 642\u2013649.","journal-title":"Leukemia"},{"key":"BFbmt2016250_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-1-4614-9437-9_8","volume":"1109","author":"E Spierings","year":"2014","unstructured":"Spierings E . Molecular typing methods for minor histocompatibility antigens. Methods Mol Biol 2014; 1109: 115\u2013138.","journal-title":"Methods Mol Biol"},{"key":"BFbmt2016250_CR35","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","volume":"97","author":"PA Rowlings","year":"1997","unstructured":"Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855\u2013864.","journal-title":"Br J Haematol"},{"key":"BFbmt2016250_CR36","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467\u20131473.","journal-title":"Leukemia"},{"key":"BFbmt2016250_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV . Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3\u20139.","journal-title":"Leukemia"},{"key":"BFbmt2016250_CR38","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/bmt.2008.14","volume":"41","author":"M Lioznov","year":"2008","unstructured":"Lioznov M, Badbaran A, Fehse B, Bacher U, Zander AR, Kroger NM . Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques. Bone Marrow Transplant 2008; 41: 913\u2013916.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016250_CR39","first-page":"5091","volume":"9","author":"IJ de Vries","year":"2003","unstructured":"de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003; 9: 5091\u20135100.","journal-title":"Clin Cancer Res"},{"key":"BFbmt2016250_CR40","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/bmt.2011.258","volume":"47","author":"K Broen","year":"2012","unstructured":"Broen K, Greupink-Draaisma A, Fredrix H, Schaap N, Dolstra H . Induction of multiple myeloma-reactive T cells during post-transplantation immunotherapy with donor lymphocytes and recipient DCs. Bone Marrow Transplant 2012; 47: 1229\u20131234.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016250_CR41","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.bbmt.2009.10.006","volume":"16","author":"H Levenga","year":"2010","unstructured":"Levenga H, Schaap N, Maas F, Esendam B, Fredrix H, Greupink-Draaisma A et al. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma. Biol Blood Marrow Transplant 2010; 16: 320\u2013332.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016250_CR42","doi-asserted-by":"publisher","first-page":"397648","DOI":"10.1155\/2012\/397648","volume":"2012","author":"TN Nguyen-Pham","year":"2012","unstructured":"Nguyen-Pham TN, Lee YK, Kim HJ, Lee JJ . Immunotherapy using dendritic cells against multiple myeloma: how to improve? Clin Dev Immunol 2012; 2012: 397648.","journal-title":"Clin Dev Immunol"},{"key":"BFbmt2016250_CR43","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3109\/10428190109064592","volume":"42","author":"S Fujii","year":"2001","unstructured":"Fujii S, Shimizu K, Fujimoto K, Kiyokawa T, Tsukamoto A, Sanada I et al. Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells. Leuk Lymphoma 2001; 42: 357\u2013369.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2016250_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/10428190500272473","volume":"47","author":"M Bendandi","year":"2006","unstructured":"Bendandi M, Rodriguez-Calvillo M, Inoges S, Lopez-Diaz de Cerio A, Perez-Simon JA, Rodriguez-Caballero A et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma 2006; 47: 29\u201337.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2016250_CR45","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ajh.21127","volume":"83","author":"T Kitawaki","year":"2008","unstructured":"Kitawaki T, Kadowaki N, Kondo T, Ishikawa T, Ichinohe T, Teramukai S et al. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia. Am J Hematol 2008; 83: 315\u2013317.","journal-title":"Am J Hematol"},{"key":"BFbmt2016250_CR46","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/ajh.23825","volume":"89","author":"VT Ho","year":"2014","unstructured":"Ho VT, Kim HT, Kao G, Cutler C, Levine J, Rosenblatt J et al. Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2014; 89: 1092\u20131096.","journal-title":"Am J Hematol"},{"key":"BFbmt2016250_CR47","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/leu.2010.115","volume":"24","author":"T Mutis","year":"2010","unstructured":"Mutis T, Brand R, Gallardo D, van Biezen A, Niederwieser D, Goulmy E . Graft-versus-host driven graft-versus-leukemia effect of minor histocompatibility antigen HA-1 in chronic myeloid leukemia patients. Leukemia 2010; 24: 1388\u20131392.","journal-title":"Leukemia"},{"key":"BFbmt2016250_CR48","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3389\/fimmu.2014.00165","volume":"5","author":"F Wimmers","year":"2014","unstructured":"Wimmers F, Schreibelt G, Skold AE, Figdor CG, De Vries IJ . Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front Immunol 2014; 5: 165.","journal-title":"Front Immunol"},{"key":"BFbmt2016250_CR49","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.coi.2013.05.001","volume":"25","author":"K Palucka","year":"2013","unstructured":"Palucka K, Banchereau J . Human dendritic cell subsets in vaccination. Curr Opin Immunol 2013; 25: 396\u2013402.","journal-title":"Curr Opin Immunol"},{"key":"BFbmt2016250_CR50","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1182\/blood-2006-04-016980","volume":"108","author":"S Wang","year":"2006","unstructured":"Wang S, Hong S, Yang J, Qian J, Zhang X, Shpall E et al. Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK\/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 2006; 108: 4071\u20134077.","journal-title":"Blood"},{"key":"BFbmt2016250_CR51","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1182\/blood-2005-06-2486","volume":"107","author":"S Wang","year":"2006","unstructured":"Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q . Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 2006; 107: 2432\u20132439.","journal-title":"Blood"},{"key":"BFbmt2016250_CR52","doi-asserted-by":"publisher","first-page":"9525","DOI":"10.1158\/0008-5472.CAN-05-0529","volume":"65","author":"Y Nefedova","year":"2005","unstructured":"Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI . Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2\/signal transducers and activators of transcription 3 pathway. Cancer Res 2005; 65: 9525\u20139535.","journal-title":"Cancer Res"},{"key":"BFbmt2016250_CR53","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00262-004-0629-2","volume":"54","author":"L Holtl","year":"2005","unstructured":"Holtl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 2005; 54: 663\u2013670.","journal-title":"Cancer Immunol Immunother"},{"key":"BFbmt2016250_CR54","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00262-012-1334-1","volume":"62","author":"W Hobo","year":"2013","unstructured":"Hobo W, Novobrantseva TI, Fredrix H, Wong J, Milstein S, Epstein-Barash H et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother 2013; 62: 285\u2013297.","journal-title":"Cancer Immunol Immunother"},{"key":"BFbmt2016250_CR55","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/bmt.2015.256","volume":"51","author":"R Oostvogels","year":"2016","unstructured":"Oostvogels R, Lokhorst HM, Mutis T . Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives. Bone Marrow Transplant 2016; 51: 163\u2013171.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2016250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016250","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T22:22:45Z","timestamp":1692570165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2016250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,14]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["BFbmt2016250"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.250","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,14]]},"assertion":[{"value":"2 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}